Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Chang VK, et al. Among authors: swindells s. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. Nat Commun. 2024. PMID: 39477924 Free PMC article. Clinical Trial.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group. Molina JM, et al. Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25. Lancet HIV. 2018. PMID: 29592840 Clinical Trial.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Molina JM, et al. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. Lancet HIV. 2020. PMID: 31740348 Clinical Trial.
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.
Furl R, Scarsi KK, Sayles H, Anderson M, Ofimboudem JD, Weld ED, Waked I, Gomaa A, Al-Khatib A, Elshobary FM, Desalegn H, Fisseha H, Solomon S, Mehta S, Owen A, Rannard S, Thomas DL, Swindells S. Furl R, et al. Among authors: swindells s. J Viral Hepat. 2024 Nov 15. doi: 10.1111/jvh.14031. Online ahead of print. J Viral Hepat. 2024. PMID: 39545599
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.
Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC; NIH COVID-19 Treatment Guidelines Panel; Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio P, Bhalla A, Burgess T, Campbell D, Cantrill S, Chew K, Chiotos K, Coopersmith C, Davey R, Dzierba A, Eisnor D, Eschenauer G, Francis J, Gallagher J, Glidden D, Goldenberg N, Grund B, Han A, Hardy E, Harrison C, Henderson L, Higgs E, Hinkson C, Hughes B, Johnson S, Keller M, Kim A, Knight R, Kuriakose S, Lennox J, Lerner A, Levy M, Li J, MacBrayne C, Martin G, Nadig N, Nason M, Patel P, Pavia A, Proschan M, Schulert G, Seam N, Sheikh V, Simpson S, Singh K, Swindells S, Tien P, Uyeki T, Waghmare A, Wolfe C, Yazdany J, Aberg J. Gulick RM, et al. Among authors: swindells s. Ann Intern Med. 2024 Nov;177(11):1547-1557. doi: 10.7326/ANNALS-24-00464. Epub 2024 Oct 1. Ann Intern Med. 2024. PMID: 39348691 Free article.
The All Together Group: Co-Designing a Toolkit of Approaches and Resources for End-of-Life Care Planning With People With Intellectual Disabilities in Social Care Settings.
Bruun A, Cresswell A, Jeffrey D, Jordan L, Keagan-Bull R, Giles J, Swindells S, Wilding M, Payne N, Gibson SL, Anderson-Kittow R, Tuffrey-Wijne I. Bruun A, et al. Among authors: swindells s. Health Expect. 2024 Aug;27(4):e14174. doi: 10.1111/hex.14174. Health Expect. 2024. PMID: 39114930 Free PMC article.
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.
Xu AY, Velásquez GE, Zhang N, Chang VK, Phillips PPJ, Nahid P, Dorman SE, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Brown NE, Engle ML, Nhung NV, Nsubuga P, Diacon A, Dooley KE, Chaisson RE, Swindells S, Savic RM. Xu AY, et al. Among authors: swindells s. Am J Respir Crit Care Med. 2024 Dec 1;210(11):1358-1369. doi: 10.1164/rccm.202401-0165OC. Am J Respir Crit Care Med. 2024. PMID: 39012226 Clinical Trial.
Facilitators and barriers to adolescent participation in a TB clinical trial.
Mangan JM, Hedges KNC, Salerno MM, Tatum K, Bouwkamp B, Frick MW, McKenna L, Muzanyi G, Engle M, Coetzee J, Yvetot J, Elskamp M, Lamunu D, Tizora MET, Namutamba D, Chaisson RE, Swindells S, Nahid P, Dorman SE, Kurbatova E. Mangan JM, et al. Among authors: swindells s. Int J Tuberc Lung Dis. 2024 May 1;28(5):243-248. doi: 10.5588/ijtld.23.0519. Int J Tuberc Lung Dis. 2024. PMID: 38659142 Free PMC article.
232 results